Boryeong Rasagiline 1mg Tablets (Rasagiline Mesylate)

Adult dose

This medicine is administered orally once daily to adults as monotherapy or adjunctive therapy. 1) Monotherapy or adjunctive therapy to a dopamine agonist: Administer 1mg orally once daily. 2) Adjunctive therapy to levodopa: The recommended initial dose for patients taking levodopa is 0.5mg once daily. If it is well tolerated and an adequate clinical response is not achieved, the dose may be increased to 1mg once daily. This medicine may be taken with or without food.

This medication should not be administered to patients who are allergic to its active ingredient or other components. Also, it should not be used in conjunction with other MAO inhibitors or natural medicines without a prescription, or if discontinued within the last 2 weeks. Especially, patients who are using or have discontinued medications such as pethidine, tramadol, or dextromethorphan within 2 weeks should not be treated with this medication. This medication should not be used in patients with moderate to severe liver impairment. Various adverse reactions may occur during the use of this medication, with common symptoms including headache, dizziness, nausea, arthralgia, and insomnia. Additionally, infections, dermatitis, musculoskeletal pain, blood pressure changes, psychiatric symptoms (depression, hallucinations), gastrointestinal symptoms (vomiting, constipation, diarrhea) have been reported. If adverse reactions are severe or persistent, consult a physician. Exceeding the recommended dosage may reduce selectivity and increase the risk of side effects, so it is essential to adhere to the prescribed dosage. For patients with Parkinson's disease, regular monitoring of skin conditions is advisable due to an increased risk of skin cancer. Additionally, those with pre-existing movement disorders or hypotension may find symptoms worsen when taking this medication. Mental or behavioral changes such as impulse control disorders, obsessive behaviors, and pathological gambling may occur while taking this medication; thus, both the patient and caregivers should recognize and closely monitor these symptoms. Patients with liver impairment may have elevated concentrations of this medication in their blood, so even patients with mild liver dysfunction should be treated with caution, and individuals with moderate to severe liver dysfunction should not use this medication. Patients with mild or moderate kidney dysfunction do not require dosage adjustments, but safety has not been established for patients with severe kidney impairment. This medication may cause drowsiness or sudden sleep, so it is advisable to avoid driving or operating hazardous machinery while taking it. Patients with a history of drowsiness or sleep attacks should exercise extra caution. Due to numerous drug interactions, especially with other MAO inhibitors, pethidine, tramadol, dextromethorphan, antidepressants, and sympathomimetics, serious side effects may occur when taken together; therefore, consultation with a physician or pharmacist is essential. There is insufficient safety information regarding the use of this medication in pregnant or breastfeeding women, so caution is advised when taking it, especially during breastfeeding as it may affect nursing. The safety and efficacy of this medication in children under 18 years of age have not been confirmed, so it is advisable not to use it. In the case of overdose, serious side effects may occur, and there is no specific antidote, so appropriate treatment should be sought immediately at a medical institution. This medication should be kept out of the reach of children and should be stored at a temperature between 1 and 25 degrees Celsius. Transferring the medication to other containers should be avoided as it may result in a decrease in quality or risk of accidents.

• Influenza
• skin cancer
• leukopenia
• allergy
• decreased appetite
• depression
• hallucination
• headache
• cerebrovascular accident
• conjunctivitis

This medication should be stored in a sealed container to prevent exposure to air or moisture. A cool place with a temperature between 1 and 25 degrees Celsius is suitable for storage.

Appearance

White round tablet

Package unit

30 tablets/box [10 tablets/PTP*3]